Clinical trail phases

Clinical trail phases

Clinical Trials

Our department is currently actively participating in the following clinical trials:


  • Alliance A011202
    • PI: Dr. Robert Gabordi
    • A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  • NSABP B-51/RTOG 1304
    • PI: Dr. Robert Gabordi
    • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy


  • NRG-BR003
    • PI: Dr. Bruce Hough
    • A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer


  • Agendia- Impact
    • PI: Dr. Robert Gabordi
    • Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)

Treatment Resistant Disease

    • PI: Dr. Bruce Hough
    • Molecular Analysis for Therapy Choice (MATCH)
  •  Arbor-Pharmaceuticals- Vigilant
    • PI: Dr. Samy Elhammady
    • Protocol AR22.001- Vigilant Observation of Gliadel WAfer ImplaNT (Vigilant) Registry to Collect Information on the Safety and Efficacy of Gliadel®